论文部分内容阅读
目的评价多烯紫杉醇(DOC)加奥沙利铂(OXA)与长春瑞滨(NVB)加奥沙利铂方案治疗老年晚期非小细胞肺癌临床疗效和安全性。方法经病理组织学或细胞学确诊为晚期非小细胞肺癌的老年患者45例(年龄>65岁)为研究对象,以1∶1比例随机分为多烯紫杉醇联合奥沙利铂(DO)组24例与长春瑞滨联合奥沙利铂(NO)组21例,DO组奥沙利铂130 mg/m2,静脉滴注2 h,第1天,多烯紫杉醇75 mg/m2,静脉滴注3 h,第2天;NO组为长春瑞滨25 mg/m2静脉滴注,第1,8天,奥沙利铂用法同DO组。每3周重复一次,均行3周期治疗,按照RECIST标准评价疗效和不良反应。结果 DO组24例,完全缓解(CR)4例,部分缓解9例(PR),稳定6(SD)例,总有效率为54.17%(13/24);NO组21例,完全缓解3例,部分缓解8例,稳定6例,总有效率52.38%(11/21)。DO组和NO组两组患者临床疗效差异无统计学意义(P>0.05)。DO组恶心、呕吐反应,血红蛋白下降和神经毒性均较NO组低。结论 DO方案与NO方案治疗老年晚期非小细胞肺癌的疗效相似,但DO方案较NO方案不良反应轻,老年患者更容易耐受,是老年晚期非小细胞肺癌较理想的化疗方法。
Objective To evaluate the clinical efficacy and safety of docetaxel (DOC) plus oxaliplatin (OXA) plus vinorelbine (NVB) plus oxaliplatin in the treatment of senile advanced non-small cell lung cancer. Methods Forty-five elderly patients (> 65 years old) diagnosed as advanced non-small cell lung cancer by histopathology or cytology were randomly divided into docetaxel and oxaliplatin (DO) groups 24 cases were treated with vinorelbine in oxaliplatin (NO) group, 21 cases, DO group oxaliplatin 130 mg / m2, intravenous infusion of 2 h, the first day, docetaxel 75 mg / m2, intravenous drip 3 h, on the 2nd day; NO group was Vinorelbine 25 mg / m2 intravenously, on the 1st and 8th day, the use of oxaliplatin was the same as the DO group. Repeat every 3 weeks, all three cycles of treatment, according to RECIST standard evaluation of efficacy and adverse reactions. Results The total effective rate was 54.17% (13/24) in DO group (24 cases), complete remission (CR) in 4 cases, partial remission in 9 cases (PR) and stable 6 (SD) , Partial remission in 8 cases, stable in 6 cases, the total effective rate was 52.38% (11/21). There was no significant difference in clinical efficacy between DO and NO groups (P> 0.05). The nausea, vomiting, hemoglobin and neurotoxicity in DO group were lower than those in NO group. Conclusions DO and NO regimen are similar in the treatment of advanced non-small cell lung cancer (NSCLC). However, DO regimen has less adverse reactions than NO regimen and elderly patients are easier to tolerate. It is an ideal chemotherapy for elderly patients with advanced non-small cell lung cancer.